H. Lundbeck A/S (LON:0ABR)

Market Cap	4.22B
Revenue (ttm)	2.44B
Net Income (ttm)	348.52M
Shares Out	n/a
EPS (ttm)	0.35
PE Ratio	12.10
Forward PE	n/a
Dividend	0.08 (0.24%)
Ex-Dividend Date	Mar 27, 2025

Volume	2,359
Average Volume	1,658
Open	34.25
Previous Close	34.05
Day's Range	33.75 - 34.55
52-Week Range	3.06 - 4.63
Beta	n/a
RSI	45.92
Earnings Date	Feb 5, 2025

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati...

• Industry: Pharmaceutical Preparations
• Founded: 1915
• Employees: 5,707
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ABR

Financial Performance

In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.

Financial numbers in DKK